Regenxbio Inc (RGNX)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	-263,494	-260,540	-274,156	-270,274	-280,321	73,637	90,716	101,256	127,840	-212,424	-145,228	-121,351	-111,250	-91,473	-134,848	-102,543	-94,733	-63,963	-48,581	-36,530
Total stockholders’ equity	US$ in thousands	311,742	363,100	405,855	465,139	516,195	563,824	630,519	689,669	764,298	461,414	507,245	554,504	377,753	415,660	397,861	420,152	450,197	468,395	494,592	487,053
ROE		-84.52%	-71.75%	-67.55%	-58.11%	-54.31%	13.06%	14.39%	14.68%	16.73%	-46.04%	-28.63%	-21.88%	-29.45%	-22.01%	-33.89%	-24.41%	-21.04%	-13.66%	-9.82%	-7.50%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-263,494K ÷ $311,742K
= -84.52%

Regenxbio Inc's return on equity (ROE) has shown a declining trend from the first quarter of 2022 to the fourth quarter of 2023. The ROE deteriorated significantly, reaching negative values in the last four quarters, indicating that the company's net income generated from shareholders' equity has been insufficient.

The negative ROE figures suggest that Regenxbio Inc has been facing challenges in generating profits relative to its equity base. This may be a concerning trend for investors as it indicates a lack of efficiency in utilizing shareholders' equity to generate returns.

The substantial decline in ROE from positive values in 2022 to negative values in 2023 raises questions about the company's financial performance and its ability to generate sustainable profits in the future. Investors may want to closely monitor the company's profitability and operational efficiency to assess its long-term viability and growth prospects.